Olink Holding AB (OLK)
23.98
-0.04
(-0.19%)
USD |
NASDAQ |
May 22, 16:00
23.98
0.00 (0.00%)
After-Hours: 20:00
Olink Revenue (TTM): 170.89M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 170.89M |
| December 31, 2023 | 169.60M |
| September 30, 2023 | 158.93M |
| June 30, 2023 | 146.55M |
| March 31, 2023 | 144.63M |
| December 31, 2022 | 139.85M |
| September 30, 2022 | 125.65M |
| Date | Value |
|---|---|
| June 30, 2022 | 113.85M |
| March 31, 2022 | 104.02M |
| December 31, 2021 | 94.97M |
| September 30, 2021 | 78.48M |
| June 30, 2021 | 69.50M |
| March 31, 2021 | 59.70M |
| December 31, 2020 | 54.07M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
54.07M
Minimum
Dec 2020
170.89M
Maximum
Mar 2024
116.48M
Average
119.75M
Median
Revenue (TTM) Benchmarks
| Thermo Fisher Scientific Inc | 42.49B |
| Abliva AB | -- |
| Karolinska Development AB | 0.1834M |
| Calliditas Therapeutics AB | 135.65M |
| Oncopeptides AB | 2.890M |